Target Name Drug Name Gene Name PDB Structure Target Status Target Action Drug Type Drug Status Drug Highest Status Disease of Drug Highest Status Source adaptor-associated kinase 1 baricitinib AAK1 5TE0; 5L4Q; 4WSQ Target in Phase 3 Clinical Trial NA Small molecular drug Drug in Phase 3 Clinical Trial Approved Rheumatoid arthritis TTD alpha-galactosidase a NA GLA 4NXS; 3TV8; 3S5Z; 3S5Y; 3LXC Literature-reported Target NA NA NA NA NA TTD angiopoietin-2 ly3127804 ANGPT2 4ZFG; 4JZC; 2GY7; 1Z3U; 1Z3S Target in Phase 2 Clinical Trial NA Monoclonal antibody Drug in Phase 2 Clinical Trial NA NA TTD angiotensin-converting enzyme captopril SLC33A1 6QS1; 6H5X; 6H5W; 6F9V; 6F9U Target in Phase 3 Clinical Trial NA Small molecular drug Drug in Phase 3 Clinical Trial Approved Hypertension TTD angiotensin-converting enzyme lisinopril SLC33A1 6QS1; 6H5X; 6H5W; 6F9V; 6F9U Target in Phase 3 Clinical Trial NA Small molecular drug Investigative Agent Approved Hypertension TTD angiotensin-converting enzyme ramipril SLC33A1 6QS1; 6H5X; 6H5W; 6F9V; 6F9U Target in Phase 3 Clinical Trial NA Small molecular drug Drug in Phase 2 Clinical Trial Approved Heart failure TTD angiotensin-converting enzyme 2 n-(2-aminoethyl)-1-aziridine-ethanamine ACE2 6CS2; 6ACK; 6ACJ; 6ACG; 3SCL Target in phase 2 Clinical Trial NA Small molecular drug Investigative Agent NA NA TTD angiotensin-converting enzyme 2 rhace2 ACE2 6CS2; 6ACK; 6ACJ; 6ACG; 3SCL Target in phase 2 Clinical Trial NA Protein/peptide drug Drug in Phase 2 Clinical Trial NA NA TTD atpase h+ transporting accessory protein 1 NA ATP6AP1 NA Literature-reported Target NA NA NA NA NA TTD basigin meplazumab BSG 5XF0; 5X0T; 4U0Q; 3QR2; 3QQN Target in Phase 1/2 Clinical Trial NA Monoclonal antibody Drug in Phase 1/2 Clinical Trial NA NA TTD beta adrenergic receptor carvedilol NA NA Investigative Target NA Small molecular drug Investigative Agent Approved Heart failure TTD bromodomain-containing protein 2 abbv-744 BRD2 6MOA; 6MO9; 6MO8; 6MO7; 6FFG Investigative Target NA Small molecular drug Investigative Agent NA NA TTD bromodomain-containing protein 2 jq1 BRD2 6MOA; 6MO9; 6MO8; 6MO7; 6FFG Investigative Target NA Small molecular drug Investigative Agent NA NA TTD bromodomain-containing protein 4 NA BRD4 6Q3Z; 6Q3Y; 6MNL; 6MAU; 6HDQ Literature-reported Target NA NA NA NA NA TTD bruton tyrosine kinase acalabrutinib BTK 6O8I; 6NFI; 6NFH; 6N9P; 6HRT Target in Phase 2 Clinical Trial NA Small molecular drug Drug in Phase 2 Clinical Trial Approved Leukemia TTD c-c chemokine receptor 5 leronlimab CCR5 6MET; 6MEO; 6FGP; 5YY4; 5YD5 Target in Phase 2 Clinical Trial NA Monoclonal antibody Drug in Phase 2 Clinical Trial NA NA TTD c-reactive protein NA CRP; PTX1 1B09; 1GNH; 1LJ7; 3L2Y; 3PVN Diagnostic Marker NA NA NA NA NA TTD c5a receptor avdoralimab C5AR1 6C1R; 6C1Q; 5O9H Target in Phase 2 Clinical Trial NA Monoclonal antibody Drug in Phase 2 Clinical Trial NA NA TTD calpain-1/calpain small subunit 1 dimer bld-2660 NA NA Target in Phase 2 Clinical Trial NA Small molecular drug Drug in Phase 2 Clinical Trial NA NA TTD calpain-2/calpain small subunit 1 dimer NA NA NA Target in Phase 2 Clinical Trial NA NA NA NA NA TTD casein kinase ii silmitasertib NA 6Q4Q; 6Q38; 6HME; 6HBN; 6GMD Investigative Target NA Small molecular drug Investigative Agent Phase 1/2 Cholangiocarcinoma TTD casein kinase ii alpha prime NA CSNK2A2 6QY9; 6HMQ; 6HMD; 6HMC; 6HMB Literature-reported Target NA NA NA NA NA TTD catechol-o-methyl-transferase NA COMT 5LSA; 4XUE; 4XUD; 4XUC; 4PYK Literature-reported Target NA NA NA NA NA TTD cathepsin l e-64d CTSL 6F06; 6EZX; 6EZP; 5MQY; 5MAJ Preclinical Target NA Small molecular drug Preclinical Drug NA NA TTD cathepsin l k11777 CTSL 6F06; 6EZX; 6EZP; 5MQY; 5MAJ Preclinical Target NA Small molecular drug Preclinical Drug NA NA TTD cathepsin l pmid26868298-compound-5705213 CTSL 6F06; 6EZX; 6EZP; 5MQY; 5MAJ Preclinical Target NA Small molecular drug Preclinical Drug NA NA TTD centrosomal protein 250 NA CEP250 NA Literature-reported Target NA NA NA NA NA TTD cholinesterase NA BCHE 6QAE; 6QAD; 6QAC; 6QAB; 6QAA Diagnostic Marker NA NA NA NA NA TTD clathrin-mediated endocytosis chlorpromazine NA NA Target in Phase 3 Clinical Trial NA Small molecular drug Drug in Phase 3 Clinical Trial, Investigative Agent Withdrawn from market Schizophrenia TTD clathrin-mediated endocytosis fluphenazine NA NA Target in Phase 3 Clinical Trial NA Small molecular drug Investigative Agent NA NA TTD clathrin-mediated endocytosis promethazine NA NA Target in Phase 3 Clinical Trial NA Small molecular drug Investigative Agent NA NA TTD clathrin-mediated endocytosis thiethylperazine NA NA Target in Phase 3 Clinical Trial NA Small molecular drug Investigative Agent NA NA TTD clathrin-mediated endocytosis triflupromazine NA NA Target in Phase 3 Clinical Trial NA Small molecular drug Investigative Agent Withdrawn from market Schizophrenia TTD colony-stimulating factor lenzilumab CSF2 6BFS; 6BFQ; 5D72; 5D71; 5D70 Target in Phase 3 Clinical Trial NA Monoclonal antibody Drug in Phase 3 Clinical Trial NA NA TTD colony-stimulating factor otilimab CSF2 6BFS; 6BFQ; 5D72; 5D71; 5D70 Target in Phase 3 Clinical Trial NA Monoclonal antibody Drug in Phase 2 Clinical Trial Phase 3 Rheumatoid arthritis TTD colony-stimulating factor tj003234 CSF2 6BFS; 6BFQ; 5D72; 5D71; 5D70 Target in Phase 3 Clinical Trial NA Monoclonal antibody Drug in Phase 1/2 Clinical Trial NA NA TTD complement c5 alpha ifx-1 C5 NA Target in Phase 2/3 Clinical Trial NA Monoclonal antibody Drug in Phase 2/3 Clinical Trial NA NA TTD complement c5 protein eculizumab C5 NA Target in Phase 3 Clinical Trial NA Monoclonal antibody Drug in Phase 2 Clinical Trial Approved Neuromyelitis optica TTD complement c5 protein ravulizumab C5 NA Target in Phase 3 Clinical Trial NA Monoclonal antibody Drug in Phase 3 Clinical Trial Approved Paroxysmal nocturnal hemoglobinuria TTD creatinine NA NA NA Diagnostic Marker NA NA NA NA NA TTD cullin-2 NA cullin 2 4WQO; 5N4W; 6R6H; 6R7F; 6R7H Literature-reported Target NA NA NA NA NA TTD cyclin g-associated kinase NA GAK 4C57; 4C58; 4C59; 4Y8D; 5Y7Z Target in Phase 3 Clinical Trial NA NA NA NA NA TTD cyclophilin a alisporivir PPIA 6GJY; 6GJR; 6GJP; 6GJN; 6GJM Investigative Target NA Protein/peptide drug Investigative Agent Phase 3 Hepatitis C virus infection TTD cyclophilin d ciclosporin PPIF 5NWO; 5CCS; 5CCR; 5CCQ; 5CCN Investigative Target NA Protein/peptide drug Investigative Agent Approved Graft-versus-host disease TTD cystatin c NA NA NA Diagnostic Marker NA NA NA NA NA TTD dctp pyrophosphatase 1 NA DCTPP1 NA Literature-reported Target NA NA NA NA NA TTD dibasic-processing enzyme dec-rvkr-cmk FURIN 6HZD; 6HZC; 6HZB; 6HZA; 6HLE Preclinical Target NA Protein/peptide drug Preclinical Drug NA NA TTD dihydroorotate dehydrogenase fa-613 DHODH 6FMD; 6ET4; 6CJG; 6CJF; 5ZFB Target in Phase 2/3 Clinical Trial NA Small molecular drug Preclinical Drug NA NA TTD dihydroorotate dehydrogenase imu-838 DHODH 6FMD; 6ET4; 6CJG; 6CJF; 5ZFB Target in Phase 2/3 Clinical Trial NA Small molecular drug Drug in Phase 2/3 Clinical Trial NA NA TTD dihydroorotate dehydrogenase leflunomide DHODH 6FMD; 6ET4; 6CJG; 6CJF; 5ZFB Target in Phase 2/3 Clinical Trial NA Small molecular drug Drug in Phase 1 Clinical Trial Approved Multiple sclerosis TTD dipeptidyl peptidase 4 linagliptin DPP4 6B1O; 6B1E; 5ZID; 5Y7K; 5Y7J Target in Phase 3 Clinical Trial NA Small molecular drug Drug in Phase 3 Clinical Trial Approved Type 2 diabetes TTD dipeptidyl peptidase 4 ys110 mab clone DPP4 6B1O; 6B1E; 5ZID; 5Y7K; 5Y7J Target in Phase 3 Clinical Trial NA Monoclonal antibody Investigative Agent NA NA TTD dna [cytosine-5]-methyltransferase 1 NA DNMT1 5YDR; 5WVO; 4Z97; 4Z96; 4YOC Literature-reported Target NA NA NA NA NA TTD erk activator kinase 1 selumetinib MAP2K1 5YT3; 5HZE; 5EYM; 5BX0; 4U81 Investigative Target NA Small molecular drug Investigative Agent Approved Neurofibromatosis type 1 TTD erk activator kinase 1 trametinib MAP2K1 5YT3; 5HZE; 5EYM; 5BX0; 4U81 Investigative Target NA Small molecular drug Investigative Agent Approved Metastatic melanoma TTD erk activator kinase 2 NA MAP2K2 4H3Q; 1S9I Investigative Target NA NA NA NA NA TTD eukaryotic initiation factor-4a silvestrol EIF4A1; EIF4A2; EIF4A3 NA Investigative Target NA Small molecular drug Investigative Agent NA NA TTD eukaryotic translation initiation factor 4e family member 2 NA EIF4E2 NA Literature-reported Target NA NA NA NA NA TTD excitatory amino acid transporter 1 NA SLC1A3; GLAST, GLAST1 5MJU; 5LM4; 5LLU; 5LLM Literature-reported Target NA NA NA NA NA TTD fk506 binding protein 10 NA FKBP10 NA Literature-reported Target NA NA NA NA NA TTD fk506 binding protein 15 NA FKBP15 NA Literature-reported Target NA NA NA NA NA TTD fk506 binding protein 7 NA FKBP7 NA Literature-reported Target NA NA NA NA NA TTD fusion protein bcr-abl dasatinib BCR-ABL1 NA Investigative Target NA Small molecular drug Investigative Agent Approved Chronic myeloid leukaemia TTD fusion protein bcr-abl imatinib BCR-ABL1 NA Investigative Target NA Small molecular drug Investigative Agent, Drug in Phase 3 Clinical Trial Approved Chronic myeloid leukaemia TTD glycosylation of host receptor NA NA NA Target in Phase 3 Clinical Trial NA NA NA NA NA TTD histone deacetylase 2 NA HDAC2 6G3O; 5IX0; 5IWG; 4LY1; 4LXZ Literature-reported Target NA NA NA NA NA TTD inosine-5'-monophosphate dehydrogenase 1 ribavirin IMPDH1 1JCN Investigative Target NA Small molecular drug Investigative Agent Approved Hepatitis C virus infection TTD inosine-5'-monophosphate dehydrogenase 2 merimepodib IMPDH2 6I0O; 6I0M; 1NFB; 1NF7; 1B3O Investigative Target NA Small molecular drug Investigative Agent Phase 2b Hepatitis C virus infection TTD interferon gamma emapalumab IFNG 6E3L; 6E3K; 3BES; 1HIG; 1FYH Target in Phase 2/3 Clinical Trial NA Monoclonal antibody Drug in Phase 2/3 Clinical Trial Approved Primary haemophagocytic lymphohistiocytosis TTD interleukin-1 beta NA IL1B 9ILB; 7I1B; 6I1B; 5MVZ; 5I1B Diagnostic Marker NA NA NA NA NA TTD interleukin-1 receptor 1 anakinra IL1R1 4GAF; 4DEP; 1ITB; 1IRA; 1G0Y Target in Phase 3 Clinical Trial NA Small molecular drug Drug in Phase 3 Clinical Trial Approved Rheumatoid arthritis TTD interleukin-10 NA IL10 2ILK; 2H24; 1Y6K; 1LK3; 1J7V Diagnostic Marker NA NA NA NA NA TTD interleukin-6 receptor sarilumab IL6R; IL6ST NA Target in Phase 3 Clinical Trial NA Monoclonal antibody Drug in Phase 3 Clinical Trial Approved Rheumatoid arthritis TTD interleukin-6 receptor tocilizumab IL6R; IL6ST NA Target in Phase 3 Clinical Trial NA Monoclonal antibody Drug in Phase 3 Clinical Trial Approved Giant cell arteritis TTD interleukin 6 clazakizumab IL6 5FUC; 4ZS7; 4O9H; 4NI9; 4NI7 Target in Phase 3 Clinical Trial; Diagnostic Marker NA Monoclonal antibody Drug in Phase 2 Clinical Trial NA NA TTD interleukin 6 olokizumab IL6 5FUC; 4ZS7; 4O9H; 4NI9; 4NI7 Target in Phase 3 Clinical Trial; Diagnostic Marker NA Monoclonal antibody Drug in Phase 2/3 Clinical Trial Phase 3 Rheumatoid Arthritis TTD interleukin 6 siltuximab IL6 5FUC; 4ZS7; 4O9H; 4NI9; 4NI7 Target in Phase 3 Clinical Trial; Diagnostic Marker NA Monoclonal antibody Drug in Phase 3 Clinical Trial Approved Idiopathic multicentric Castleman disease TTD interleukin 6 sirukumab IL6 5FUC; 4ZS7; 4O9H; 4NI9; 4NI7 Target in Phase 3 Clinical Trial; Diagnostic Marker NA Monoclonal antibody Drug in Phase 2 Clinical Trial Phase 3 Rheumatoid arthritis TTD interleukin 8 bms-986253 CXCL8 5WDZ; 5D14; 4XDX; 3IL8; 2IL8 Target in Phase 2 Clinical Trial NA Monoclonal antibody Drug in Phase 2 Clinical Trial NA NA TTD janus kinase 1 ruxolitinib JAK1 6N7D; 6N7C; 6N7B; 6N7A; 6N79 Target in Phase 3 Clinical Trial NA Small molecular drug Drug in Phase 3 Clinical Trial Approved Myelofibrosis TTD janus kinase 2 fedratinib JAK2 6M9H; 6E2Q; 6E2P; 6DRW; 6BSS Target in Phase 3 Clinical Trial NA Small molecular drug Investigative Agent Approved Polycythemia vera TTD l-lactate dehydrogenase NA LDHA; LDHB; LDHC NA Diagnostic Marker NA NA NA NA NA TTD la-related protein 1 NA LARP1 4ZC4; 5C0V; 5V4R; 5V7C; 5V87 Literature-reported Target NA NA NA NA NA TTD lysyl hydroxylase 2 NA PLOD2 NA Literature-reported Target NA NA NA NA NA TTD lysyl oxidase NA LOX NA Literature-reported Target NA NA NA NA NA TTD mammalian target of rapamycin everolimus MTOR 6BCX; 6BCU; 5ZCS; 5WBY; 5WBU Target in Phase 2 Clinical Trial NA Small molecular drug Investigative Agent Approved Advanced/metastatic breast cancer TTD mammalian target of rapamycin rapamycin MTOR 6BCX; 6BCU; 5ZCS; 5WBY; 5WBU Target in Phase 2 Clinical Trial NA Small molecular drug Investigative Agent Approved Lymphangioleiomyomatosis TTD mammalian target of rapamycin sapanisertib MTOR 6BCX; 6BCU; 5ZCS; 5WBY; 5WBU Target in Phase 2 Clinical Trial NA Small molecular drug Investigative Agent Phase 2 Breast Cancer TTD mammalian target of rapamycin sirolimus MTOR 6BCX; 6BCU; 5ZCS; 5WBY; 5WBU Target in Phase 2 Clinical Trial NA Small molecular drug Drug in Phase 2 Clinical Trial Approved Lymphangioleiomyomatosis TTD mannose receptor metformin MRC1 5XTW; 5XTS; 1EGI; 1EGG Investigative Target NA Small molecular drug Investigative Agent Approved Type 2 diabetes TTD microtubule affinity regulating kinase 2 NA MARK2 3IEC; 5EAK; 5KZ7; 5KZ8 Literature-reported Target NA NA NA NA NA TTD microtubule affinity regulating kinase 3 NA MARK3 3FE3; 2QNJ Literature-reported Target NA NA NA NA NA TTD multidrug resistance-associated protein 1 NA ABCC1 4C3Z; 2CBZ Literature-reported Target NA NA NA NA NA TTD myd88-nf-kappa-b proinflammatory pathway atorvastatin NA NA Target in Phase 2 Clinical Trial NA Small molecular drug Drug in Phase 2 Clinical Trial Approved Hyperlipidemia TTD nadh:ubiquinone oxidoreductase complex assembly factor 2 NA NDUFAF2 NA Literature-reported Target NA NA NA NA NA TTD nadh:ubiquinone oxidoreductase subunit b9 NA NDUFB9 5XTC; 5XTD; 5XTH; 5XTI Literature-reported Target NA NA NA NA NA TTD nf-kappa-b-activating kinase NA TBK1 6O8B; 6NT9; 6CQ5; 6CQ4; 6CQ0 Literature-reported Target NA NA NA NA NA TTD nima related kinase 9 NA NEK9 3ZKE; 3ZKF Literature-reported Target NA NA NA NA NA TTD opioid receptor sigma 1 e-52862 SIGMAR1 6DK1; 6DK0; 6DJZ; 5HK2; 5HK1 Investigative Target NA Small molecular drug Investigative Agent NA NA TTD opioid receptor sigma 1 haloperidol SIGMAR1 6DK1; 6DK0; 6DJZ; 5HK2; 5HK1 Investigative Target NA Small molecular drug Investigative Agent Approved Schizophrenia TTD opioid receptor sigma 1 pb28 SIGMAR1 6DK1; 6DK0; 6DJZ; 5HK2; 5HK1 Investigative Target NA Small molecular drug Investigative Agent NA NA TTD opioid receptor sigma 1 pd-144418 SIGMAR1 6DK1; 6DK0; 6DJZ; 5HK2; 5HK1 Investigative Target NA Small molecular drug Investigative Agent NA NA TTD opioid receptor sigma 1 rs-ppcc SIGMAR1 6DK1; 6DK0; 6DJZ; 5HK2; 5HK1 Investigative Target NA Small molecular drug Investigative Agent NA NA TTD ph-dependent viral fusion/replication chloroquine NA NA Target in Phase 3 Clinical Trial NA Small molecular drug Drug in Phase 3 Clinical Trial, Investigative Agent Withdrawn from market Malaria TTD phosphodiesterase type 5 sildenafil PDE5A 6ACB; 5ZZ2; 5JO3; 4OEX; 4OEW Target in Phase 3 Clinical Trial NA Small molecular drug Drug in Phase 3 Clinical Trial Approved Erectile dysfunction TTD pi3-kinase delta duvelisib PIK3CD 6G6W; 5VLR; 5UBT; 5T8F; 5M6U Target in Phase 2 Clinical Trial NA Small molecular drug Drug in Phase 2 Clinical Trial Approved Follicular lymphoma TTD pi3-kinase gamma NA PIK3CG 6GQ7; 6FH5; 6C1S; 6AUD; 5T23 Target in Phase 2 Clinical Trial NA NA NA NA NA TTD prostaglandin e synthase 2 NA PTGES2 NA Literature-reported Target NA NA NA NA NA TTD protein kinase camp-activated catalytic subunit alpha NA PRKACA 2GU8; 3AGL; 3AGM; 3AMA; 3AMB Literature-reported Target NA NA NA NA NA TTD proteinase activated receptor 2 NA F2RL1 5NJ6; 5NDZ; 5NDD Literature-reported Target NA NA NA NA NA TTD receptor-interacting protein 1 NA RIPK1 6R5F; 6OCQ; 6NW2; 6HHO; 6C4D Literature-reported Target NA NA NA NA NA TTD serum direct bilirubin NA NA NA Diagnostic Marker NA NA NA NA NA TTD serum urea NA NA NA Diagnostic Marker NA NA NA NA NA TTD sigma intracellular receptor 2 NA TMEM97 NA Investigative Target NA NA NA NA NA TTD sodium pump subunit alpha-1 acocantherin ATP1A1 NA Investigative Target NA Small molecular drug Investigative Agent NA NA TTD solute carrier family 6 member 15 NA SLC6A15 NA Literature-reported Target NA NA NA NA NA TTD toll-like receptor 2 pul-042 TLR2 6NIG; 2Z80; 2Z7X; 1O77; 1FYX Target in Phase 2 Clinical Trial NA Protein/peptide drug Drug in Phase 2 Clinical Trial NA NA TTD toll-like receptor 3 polyinosinic:polycytidylic acid TLR3 5GS0; 3ULV; 3ULU; 2MKA; 2MK9 Target in Phase 1/2 Clinical Trial NA Small molecular drug Investigative Agent NA NA TTD toll-like receptor 3 rintatolimod TLR3 5GS0; 3ULV; 3ULU; 2MKA; 2MK9 Target in Phase 1/2 Clinical Trial NA Small molecular drug Drug in Phase 1/2 Clinical Trial Phase 3 Chronic Fatigue Syndrome TTD toll-like receptor 6 NA TLR6 4OM7 Target in Phase 2 Clinical Trial NA NA NA NA NA TTD toll-like receptor 7/9 signalling pathways azithromycin + hydroxychloroquine NA NA Target in Phase 3 Clinical Trial NA Combination drug Drug in Phase 3 Clinical Trial NA NA TTD toll-like receptor 7/9 signalling pathways darunavir + ritonavir + favipiravir + hydroxychloroquine NA NA Target in Phase 3 Clinical Trial NA Combination drug Drug in Phase 3 Clinical Trial NA NA TTD toll-like receptor 7/9 signalling pathways darunavir + ritonavir + oseltamivir + hydroxychloroquine NA NA Target in Phase 3 Clinical Trial NA Combination drug Drug in Phase 3 Clinical Trial NA NA TTD toll-like receptor 7/9 signalling pathways hydroxychloroquine NA NA Target in Phase 3 Clinical Trial NA Small molecular drug Drug in Phase 3 Clinical Trial Approved Malaria TTD toll-like receptor 7/9 signalling pathways oseltamivir + hydroxychloroquine NA NA Target in Phase 3 Clinical Trial NA Combination drug Drug in Phase 3 Clinical Trial NA NA TTD toll-like receptor 9 NA TLR9 NA Target in Phase 2 Clinical Trial NA NA NA NA NA TTD transmembrane protease serine 2 camostat mesylate TMPRSS2 NA Target in Phase 2 Clinical Trial NA Small molecular drug Drug in Phase 2 Clinical Trial, Investigative Agent NA NA TTD tumor necrosis factor NA TNF 5YOY; 5WUX; 5UUI; 5TSW; 5MU8 Diagnostic Marker NA NA NA NA NA TTD two pore channel subtype 2 amiodarone TPCN2 6NQ2; 6NQ1; 6NQ0 Target in Phase 2/3 Clinical Trial NA Small molecular drug Drug in Phase 2/3 Clinical Trial Approved Ventricular tachycardia TTD two pore channel subtype 2 verapamil TPCN2 6NQ2; 6NQ1; 6NQ0 Target in Phase 2/3 Clinical Trial NA Small molecular drug Drug in Phase 2/3 Clinical Trial Approved High blood pressure TTD type-1 angiotensin ii receptor irbesartan AGTR1 6DO1; 4ZUD; 4YAY; 1ZV0 Target in Phase 3 Clinical Trial NA Small molecular drug Investigative Agent Approved Hypertension TTD type-1 angiotensin ii receptor losartan AGTR1 6DO1; 4ZUD; 4YAY; 1ZV0 Target in Phase 3 Clinical Trial NA Small molecular drug Drug in Phase 3 Clinical Trial Approved Hypertension TTD type-1 angiotensin ii receptor telmisartan AGTR1 6DO1; 4ZUD; 4YAY; 1ZV0 Target in Phase 3 Clinical Trial NA Small molecular drug Drug in Phase 3 Clinical Trial Approved Hypertension TTD vacuolar-type proton atpase catalytic a NA ATP6V1A NA Literature-reported Target NA NA NA NA NA TTD valosin-containing protein p97 nms-873 VCP 6MCK; 6G30; 6G2Z; 6G2Y; 6G2X Investigative Target NA Small molecular drug Investigative Agent NA NA TTD vascular endothelial growth factor bevacizumab NO-GeName NA Target in Phase 2/3 Clinical Trial NA Monoclonal antibody Drug in Phase 2/3 Clinical Trial Approved Metastatic colorectal cancer TTD 3-phosphoinositide-dependent protein kinase 1 fostamatinib PDPK1 NA NA inhibitor small molecule approved,investigational NA NA Drugbank 5'-amp-activated protein kinase fostamatinib PRKAA1,PRKAA2,PRKAB1,PRKAB2,PRKAG1,PRKAG2,PRKAG3 NA NA inhibitor small molecule approved,investigational NA NA Drugbank 5'-amp-activated protein kinase catalytic subunit alpha-1 fostamatinib PRKAA1 NA NA inhibitor small molecule approved,investigational NA NA Drugbank 5'-nucleotidase pentoxifylline NT5E NA NA inhibitor small molecule approved,investigational NA NA Drugbank activated cdc42 kinase 1 fostamatinib TNK2 NA NA inhibitor small molecule approved,investigational NA NA Drugbank activin receptor type-1 fostamatinib ACVR1 NA NA inhibitor small molecule approved,investigational NA NA Drugbank activin receptor type-1b fostamatinib ACVR1B NA NA inhibitor small molecule approved,investigational NA NA Drugbank adenosine receptor a1 pentoxifylline ADORA1 NA NA N/A small molecule approved,investigational NA NA Drugbank adenosine receptor a2a pentoxifylline ADORA2A NA NA agonist small molecule approved,investigational NA NA Drugbank adenosine receptor a3 fostamatinib ADORA3 NA NA antagonist small molecule approved,investigational NA NA Drugbank alk tyrosine kinase receptor fostamatinib ALK NA NA inhibitor small molecule approved,investigational NA NA Drugbank angiopoietin-1 receptor fostamatinib TEK NA NA inhibitor small molecule approved,investigational NA NA Drugbank angiotensin-converting enzyme 2 bromhexine ACE2 NA NA binder small molecule approved NA NA Drugbank angiotensin-converting enzyme 2 chloroquine ACE2 NA NA modulator small molecule approved,investigational,vet_approved NA NA Drugbank angiotensin-converting enzyme 2 hydroxychloroquine ACE2 NA NA modulator small molecule approved NA NA Drugbank ankyrin repeat and protein kinase domain-containing protein 1 fostamatinib ANKK1 NA NA inhibitor small molecule approved,investigational NA NA Drugbank annexin a1 dexamethasone ANXA1 NA NA agonist small molecule approved,investigational,vet_approved NA NA Drugbank annexin a1 dexamethasone acetate ANXA1 NA NA agonist small molecule approved,investigational,vet_approved NA NA Drugbank annexin a1 methylprednisolone ANXA1 NA NA agonist small molecule approved,vet_approved NA NA Drugbank ap2-associated protein kinase 1 fostamatinib AAK1 NA NA inhibitor small molecule approved,investigational NA NA Drugbank arachidonate 5-lipoxygenase fostamatinib ALOX5 NA NA inhibitor small molecule approved,investigational NA NA Drugbank atp-binding cassette sub-family g member 2 azvudine ABCG2 NA NA regulator small molecule investigational NA NA Drugbank atypical kinase coq8a, mitochondrial fostamatinib COQ8A NA NA inhibitor small molecule approved,investigational NA NA Drugbank atypical kinase coq8b, mitochondrial fostamatinib COQ8B NA NA inhibitor small molecule approved,investigational NA NA Drugbank aurora kinase a fostamatinib AURKA NA NA inhibitor small molecule approved,investigational NA NA Drugbank aurora kinase b fostamatinib AURKB NA NA inhibitor small molecule approved,investigational NA NA Drugbank aurora kinase c fostamatinib AURKC NA NA inhibitor small molecule approved,investigational NA NA Drugbank bdnf/nt-3 growth factors receptor fostamatinib NTRK2 NA NA inhibitor small molecule approved,investigational NA NA Drugbank bmp-2-inducible protein kinase fostamatinib BMP2K NA NA inhibitor small molecule approved,investigational NA NA Drugbank bone morphogenetic protein receptor type-1b fostamatinib BMPR1B NA NA inhibitor small molecule approved,investigational NA NA Drugbank bone morphogenetic protein receptor type-2 fostamatinib BMPR2 NA NA inhibitor small molecule approved,investigational NA NA Drugbank c-c chemokine receptor type 5 leronlimab CCR5 NA NA antagonist biotech investigational NA NA Drugbank calcium/calmodulin-dependent protein kinase kinase 1 fostamatinib CAMKK1 NA NA inhibitor small molecule approved,investigational NA NA Drugbank calcium/calmodulin-dependent protein kinase kinase 2 fostamatinib CAMKK2 NA NA inhibitor small molecule approved,investigational NA NA Drugbank calcium/calmodulin-dependent protein kinase type 1 fostamatinib CAMK1 NA NA inhibitor small molecule approved,investigational NA NA Drugbank calcium/calmodulin-dependent protein kinase type 1d fostamatinib CAMK1D NA NA inhibitor small molecule approved,investigational NA NA Drugbank calcium/calmodulin-dependent protein kinase type 1g fostamatinib CAMK1G NA NA inhibitor small molecule approved,investigational NA NA Drugbank calcium/calmodulin-dependent protein kinase type ii subunit alpha fostamatinib CAMK2A NA NA inhibitor small molecule approved,investigational NA NA Drugbank calcium/calmodulin-dependent protein kinase type ii subunit beta fostamatinib CAMK2B NA NA inhibitor small molecule approved,investigational NA NA Drugbank calcium/calmodulin-dependent protein kinase type ii subunit delta fostamatinib CAMK2D NA NA inhibitor small molecule approved,investigational NA NA Drugbank calcium/calmodulin-dependent protein kinase type ii subunit gamma fostamatinib CAMK2G NA NA inhibitor small molecule approved,investigational NA NA Drugbank camp-dependent protein kinase catalytic subunit alpha fostamatinib PRKACA NA NA inhibitor small molecule approved,investigational NA NA Drugbank camp-dependent protein kinase catalytic subunit beta fostamatinib PRKACB NA NA inhibitor small molecule approved,investigational NA NA Drugbank canalicular multispecific organic anion transporter 1 azvudine ABCC2 NA NA regulator small molecule investigational NA NA Drugbank casein kinase i isoform alpha fostamatinib CSNK1A1 NA NA inhibitor small molecule approved,investigational NA NA Drugbank casein kinase ii subunit alpha fostamatinib CSNK2A1 NA NA inhibitor small molecule approved,investigational NA NA Drugbank casein kinase ii subunit alpha' fostamatinib CSNK2A2 NA NA inhibitor small molecule approved,investigational NA NA Drugbank cathepsin l1 fostamatinib CTSL NA NA inhibitor small molecule approved,investigational NA NA Drugbank cathepsin s fostamatinib CTSS NA NA inhibitor small molecule approved,investigational NA NA Drugbank cgmp-dependent protein kinase 2 fostamatinib PRKG2 NA NA inhibitor small molecule approved,investigational NA NA Drugbank cgmp-specific 3',5'-cyclic phosphodiesterase fostamatinib PDE5A NA NA inhibitor small molecule approved,investigational NA NA Drugbank cholecystokinin camostat CCK NA NA inhibitor small molecule experimental NA NA Drugbank citron rho-interacting kinase fostamatinib CIT NA NA inhibitor small molecule approved,investigational NA NA Drugbank clip-associating protein 1 fostamatinib CLASP1 NA NA inhibitor small molecule approved,investigational NA NA Drugbank complement c1q subcomponent subunit a bevacizumab C1QA NA NA N/A biotech approved,investigational NA NA Drugbank complement c1q subcomponent subunit b bevacizumab C1QB NA NA N/A biotech approved,investigational NA NA Drugbank complement c1q subcomponent subunit c bevacizumab C1QC NA NA N/A biotech approved,investigational NA NA Drugbank complement c5 ravulizumab C5 NA NA inhibitor biotech approved,investigational NA NA Drugbank complement c5 vilobelimab C5 NA NA inhibitor biotech investigational NA NA Drugbank cyclin-dependent kinase-like 1 fostamatinib CDKL1 NA NA inhibitor small molecule approved,investigational NA NA Drugbank cyclin-dependent kinase-like 2 fostamatinib CDKL2 NA NA inhibitor small molecule approved,investigational NA NA Drugbank cyclin-dependent kinase 1 fostamatinib CDK1 NA NA inhibitor small molecule approved,investigational NA NA Drugbank cyclin-dependent kinase 15 fostamatinib CDK15 NA NA inhibitor small molecule approved,investigational NA NA Drugbank cyclin-dependent kinase 16 fostamatinib CDK16 NA NA inhibitor small molecule approved,investigational NA NA Drugbank cyclin-dependent kinase 17 fostamatinib CDK17 NA NA inhibitor small molecule approved,investigational NA NA Drugbank cyclin-dependent kinase 4 fostamatinib CDK4 NA NA inhibitor small molecule approved,investigational NA NA Drugbank cyclin-g-associated kinase fostamatinib GAK NA NA inhibitor small molecule approved,investigational NA NA Drugbank cytoplasmic tyrosine-protein kinase bmx fostamatinib BMX NA NA inhibitor small molecule approved,investigational NA NA Drugbank death-associated protein kinase 1 fostamatinib DAPK1 NA NA inhibitor small molecule approved,investigational NA NA Drugbank death-associated protein kinase 2 fostamatinib DAPK2 NA NA inhibitor small molecule approved,investigational NA NA Drugbank death-associated protein kinase 3 fostamatinib DAPK3 NA NA inhibitor small molecule approved,investigational NA NA Drugbank delta-type opioid receptor metenkefalin OPRD1 NA NA agonist small molecule investigational NA NA Drugbank discoidin domain-containing receptor 2 fostamatinib DDR2 NA NA inhibitor small molecule approved,investigational NA NA Drugbank dna hydroxychloroquine N/A NA NA cross-linking/alkylation small molecule approved NA NA Drugbank dual specificity mitogen-activated protein kinase kinase 2 fostamatinib MAP2K2 NA NA inhibitor small molecule approved,investigational NA NA Drugbank dual specificity mitogen-activated protein kinase kinase 3 fostamatinib MAP2K3 NA NA inhibitor small molecule approved,investigational NA NA Drugbank dual specificity mitogen-activated protein kinase kinase 5 fostamatinib MAP2K5 NA NA inhibitor small molecule approved,investigational NA NA Drugbank dual specificity mitogen-activated protein kinase kinase 6 fostamatinib MAP2K6 NA NA inhibitor small molecule approved,investigational NA NA Drugbank dual specificity protein kinase clk1 fostamatinib CLK1 NA NA inhibitor small molecule approved,investigational NA NA Drugbank dual specificity protein kinase clk2 fostamatinib CLK2 NA NA inhibitor small molecule approved,investigational NA NA Drugbank dual specificity protein kinase clk3 fostamatinib CLK3 NA NA inhibitor small molecule approved,investigational NA NA Drugbank dual specificity protein kinase clk4 fostamatinib CLK4 NA NA inhibitor small molecule approved,investigational NA NA Drugbank dual specificity protein kinase ttk fostamatinib TTK NA NA inhibitor small molecule approved,investigational NA NA Drugbank dual specificity testis-specific protein kinase 1 fostamatinib TESK1 NA NA inhibitor small molecule approved,investigational NA NA Drugbank dual specificity tyrosine-phosphorylation-regulated kinase 1a fostamatinib DYRK1A NA NA inhibitor small molecule approved,investigational NA NA Drugbank dual specificity tyrosine-phosphorylation-regulated kinase 1b fostamatinib DYRK1B NA NA inhibitor small molecule approved,investigational NA NA Drugbank eif-2-alpha kinase gcn2 fostamatinib EIF2AK4 NA NA inhibitor small molecule approved,investigational NA NA Drugbank ephrin type-a receptor 1 fostamatinib EPHA1 NA NA inhibitor small molecule approved,investigational NA NA Drugbank ephrin type-a receptor 2 fostamatinib EPHA2 NA NA inhibitor small molecule approved,investigational NA NA Drugbank ephrin type-a receptor 3 fostamatinib EPHA3 NA NA inhibitor small molecule approved,investigational NA NA Drugbank ephrin type-a receptor 4 fostamatinib EPHA4 NA NA inhibitor small molecule approved,investigational NA NA Drugbank ephrin type-a receptor 5 fostamatinib EPHA5 NA NA inhibitor small molecule approved,investigational NA NA Drugbank ephrin type-a receptor 6 fostamatinib EPHA6 NA NA inhibitor small molecule approved,investigational NA NA Drugbank ephrin type-a receptor 7 fostamatinib EPHA7 NA NA inhibitor small molecule approved,investigational NA NA Drugbank ephrin type-a receptor 8 fostamatinib EPHA8 NA NA inhibitor small molecule approved,investigational NA NA Drugbank ephrin type-b receptor 1 fostamatinib EPHB1 NA NA inhibitor small molecule approved,investigational NA NA Drugbank ephrin type-b receptor 2 fostamatinib EPHB2 NA NA inhibitor small molecule approved,investigational NA NA Drugbank ephrin type-b receptor 4 fostamatinib EPHB4 NA NA inhibitor small molecule approved,investigational NA NA Drugbank ephrin type-b receptor 6 fostamatinib EPHB6 NA NA inhibitor small molecule approved,investigational NA NA Drugbank epidermal growth factor receptor abivertinib EGFR NA NA inhibitor small molecule investigational NA NA Drugbank epidermal growth factor receptor fostamatinib EGFR NA NA inhibitor small molecule approved,investigational NA NA Drugbank epithelial discoidin domain-containing receptor 1 fostamatinib DDR1 NA NA inhibitor small molecule approved,investigational NA NA Drugbank equilibrative nucleoside transporter 1 fostamatinib SLC29A1 NA NA inhibitor small molecule approved,investigational NA NA Drugbank eukaryotic translation initiation factor 2-alpha kinase 1 fostamatinib EIF2AK1 NA NA inhibitor small molecule approved,investigational NA NA Drugbank fatty-acid amide hydrolase 1 fostamatinib FAAH NA NA inhibitor small molecule approved,investigational NA NA Drugbank fibroblast growth factor receptor 1 fostamatinib FGFR1 NA NA inhibitor small molecule approved,investigational NA NA Drugbank fibroblast growth factor receptor 2 fostamatinib FGFR2 NA NA inhibitor small molecule approved,investigational NA NA Drugbank fibroblast growth factor receptor 3 fostamatinib FGFR3 NA NA inhibitor small molecule approved,investigational NA NA Drugbank focal adhesion kinase 1 fostamatinib PTK2 NA NA inhibitor small molecule approved,investigational NA NA Drugbank g protein-activated inward rectifier potassium channel 1 ifenprodil KCNJ3 NA NA antagonist small molecule investigational,withdrawn NA NA Drugbank g protein-activated inward rectifier potassium channel 2 ifenprodil KCNJ6 NA NA antagonist small molecule investigational,withdrawn NA NA Drugbank g protein-activated inward rectifier potassium channel 4 ifenprodil KCNJ5 NA NA antagonist small molecule investigational,withdrawn NA NA Drugbank glucocorticoid receptor dexamethasone NR3C1 NA NA agonist small molecule approved,investigational,vet_approved NA NA Drugbank glucocorticoid receptor dexamethasone acetate NR3C1 NA NA agonist small molecule approved,investigational,vet_approved NA NA Drugbank glucocorticoid receptor methylprednisolone NR3C1 NA NA agonist small molecule approved,vet_approved NA NA Drugbank glutamate receptor ionotropic, nmda 1 ifenprodil GRIN1 NA NA antagonist small molecule investigational,withdrawn NA NA Drugbank glutamate receptor ionotropic, nmda 2b ifenprodil GRIN2B NA NA antagonist small molecule investigational,withdrawn NA NA Drugbank glutathione s-transferase a2 chloroquine GSTA2 NA NA inhibitor small molecule approved,investigational,vet_approved NA NA Drugbank glutathione s-transferase mu 1 chloroquine GSTM1 NA NA inhibitor small molecule approved,investigational,vet_approved NA NA Drugbank glycogen synthase kinase-3 alpha fostamatinib GSK3A NA NA inhibitor small molecule approved,investigational NA NA Drugbank glycogen synthase kinase-3 beta fostamatinib GSK3B NA NA inhibitor small molecule approved,investigational NA NA Drugbank hepatocyte growth factor receptor fostamatinib MET NA NA inhibitor small molecule approved,investigational NA NA Drugbank high affinity immunoglobulin gamma fc receptor i bevacizumab FCGR1A NA NA N/A biotech approved,investigational NA NA Drugbank high affinity nerve growth factor receptor fostamatinib NTRK1 NA NA inhibitor small molecule approved,investigational NA NA Drugbank high mobility group protein b1 chloroquine HMGB1 NA NA inhibitor small molecule approved,investigational,vet_approved NA NA Drugbank histone deacetylase 1 fingolimod HDAC1 NA NA inhibitor small molecule approved,investigational NA NA Drugbank homeodomain-interacting protein kinase 2 fostamatinib HIPK2 NA NA inhibitor small molecule approved,investigational NA NA Drugbank homeodomain-interacting protein kinase 3 fostamatinib HIPK3 NA NA inhibitor small molecule approved,investigational NA NA Drugbank inhibitor of nuclear factor kappa-b kinase subunit beta fostamatinib IKBKB NA NA inhibitor small molecule approved,investigational NA NA Drugbank inhibitor of nuclear factor kappa-b kinase subunit epsilon fostamatinib IKBKE NA NA inhibitor small molecule approved,investigational NA NA Drugbank insulin receptor fostamatinib INSR NA NA inhibitor small molecule approved,investigational NA NA Drugbank insulin receptor-related protein fostamatinib INSRR NA NA inhibitor small molecule approved,investigational NA NA Drugbank integrin alpha-v pln-74809 ITGAV NA NA N/A small molecule investigational NA NA Drugbank integrin beta-1 pln-74809 ITGB1 NA NA N/A small molecule investigational NA NA Drugbank integrin beta-6 pln-74809 ITGB6 NA NA N/A small molecule investigational NA NA Drugbank interferon-induced, double-stranded rna-activated protein kinase fostamatinib EIF2AK2 NA NA inhibitor small molecule approved,investigational NA NA Drugbank interferon alpha/beta receptor 1 human interferon beta IFNAR1 NA NA binder biotech approved,investigational NA NA Drugbank interleukin-1 receptor-associated kinase 1 fostamatinib IRAK1 NA NA inhibitor small molecule approved,investigational NA NA Drugbank interleukin-1 receptor-associated kinase 3 fostamatinib IRAK3 NA NA inhibitor small molecule approved,investigational NA NA Drugbank interleukin-1 receptor-associated kinase 4 fostamatinib IRAK4 NA NA inhibitor small molecule approved,investigational NA NA Drugbank interleukin-1 receptor type 1 anakinra IL1R1 NA NA antagonist biotech approved,investigational NA NA Drugbank interleukin-6 receptor subunit alpha tocilizumab IL6R NA NA inhibitor,antibody biotech approved NA NA Drugbank kappa-casein fostamatinib CSN3 NA NA inhibitor small molecule approved,investigational NA NA Drugbank leucine-rich repeat serine/threonine-protein kinase 2 fostamatinib LRRK2 NA NA inhibitor small molecule approved,investigational NA NA Drugbank leukocyte tyrosine kinase receptor fostamatinib LTK NA NA inhibitor small molecule approved,investigational NA NA Drugbank lim domain kinase 1 fostamatinib LIMK1 NA NA inhibitor small molecule approved,investigational NA NA Drugbank lim domain kinase 2 fostamatinib LIMK2 NA NA inhibitor small molecule approved,investigational NA NA Drugbank low affinity immunoglobulin gamma fc region receptor ii-a bevacizumab FCGR2A NA NA N/A biotech approved,investigational NA NA Drugbank low affinity immunoglobulin gamma fc region receptor ii-b bevacizumab FCGR2B NA NA N/A biotech approved,investigational NA NA Drugbank low affinity immunoglobulin gamma fc region receptor ii-c bevacizumab FCGR2C NA NA N/A biotech approved,investigational NA NA Drugbank low affinity immunoglobulin gamma fc region receptor iii-a bevacizumab FCGR3A NA NA N/A biotech approved,investigational NA NA Drugbank macrophage-stimulating protein receptor fostamatinib MST1R NA NA inhibitor small molecule approved,investigational NA NA Drugbank macrophage colony-stimulating factor 1 receptor fostamatinib CSF1R NA NA inhibitor small molecule approved,investigational NA NA Drugbank map kinase-activated protein kinase 5 fostamatinib MAPKAPK5 NA NA inhibitor small molecule approved,investigational NA NA Drugbank map kinase-interacting serine/threonine-protein kinase 1 fostamatinib MKNK1 NA NA inhibitor small molecule approved,investigational NA NA Drugbank map kinase-interacting serine/threonine-protein kinase 2 fostamatinib MKNK2 NA NA inhibitor small molecule approved,investigational NA NA Drugbank map/microtubule affinity-regulating kinase 3 fostamatinib MARK3 NA NA inhibitor small molecule approved,investigational NA NA Drugbank map/microtubule affinity-regulating kinase 4 fostamatinib MARK4 NA NA inhibitor small molecule approved,investigational NA NA Drugbank mast/stem cell growth factor receptor kit fostamatinib KIT NA NA inhibitor small molecule approved,investigational NA NA Drugbank maternal embryonic leucine zipper kinase fostamatinib MELK NA NA inhibitor small molecule approved,investigational NA NA Drugbank megakaryocyte-associated tyrosine-protein kinase fostamatinib MATK NA NA inhibitor small molecule approved,investigational NA NA Drugbank membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase fostamatinib PKMYT1 NA NA inhibitor small molecule approved,investigational NA NA Drugbank microtubule-associated serine/threonine-protein kinase 1 fostamatinib MAST1 NA NA inhibitor small molecule approved,investigational NA NA Drugbank misshapen-like kinase 1 fostamatinib MINK1 NA NA inhibitor small molecule approved,investigational NA NA Drugbank mitogen-activated protein kinase 10 fostamatinib MAPK10 NA NA inhibitor small molecule approved,investigational NA NA Drugbank mitogen-activated protein kinase 13 fostamatinib MAPK13 NA NA inhibitor small molecule approved,investigational NA NA Drugbank mitogen-activated protein kinase 14 fostamatinib MAPK14 NA NA inhibitor small molecule approved,investigational NA NA Drugbank mitogen-activated protein kinase 15 fostamatinib MAPK15 NA NA inhibitor small molecule approved,investigational NA NA Drugbank mitogen-activated protein kinase 4 fostamatinib MAPK4 NA NA inhibitor small molecule approved,investigational NA NA Drugbank mitogen-activated protein kinase 7 fostamatinib MAPK7 NA NA inhibitor small molecule approved,investigational NA NA Drugbank mitogen-activated protein kinase 9 fostamatinib MAPK9 NA NA inhibitor small molecule approved,investigational NA NA Drugbank mitogen-activated protein kinase kinase kinase 1 fostamatinib MAP3K1 NA NA inhibitor small molecule approved,investigational NA NA Drugbank mitogen-activated protein kinase kinase kinase 10 fostamatinib MAP3K10 NA NA inhibitor small molecule approved,investigational NA NA Drugbank mitogen-activated protein kinase kinase kinase 11 fostamatinib MAP3K11 NA NA inhibitor small molecule approved,investigational NA NA Drugbank mitogen-activated protein kinase kinase kinase 12 fostamatinib MAP3K12 NA NA inhibitor small molecule approved,investigational NA NA Drugbank mitogen-activated protein kinase kinase kinase 13 fostamatinib MAP3K13 NA NA inhibitor small molecule approved,investigational NA NA Drugbank mitogen-activated protein kinase kinase kinase 15 fostamatinib MAP3K15 NA NA inhibitor small molecule approved,investigational NA NA Drugbank mitogen-activated protein kinase kinase kinase 19 fostamatinib MAP3K19 NA NA inhibitor small molecule approved,investigational NA NA Drugbank mitogen-activated protein kinase kinase kinase 2 fostamatinib MAP3K2 NA NA inhibitor small molecule approved,investigational NA NA Drugbank mitogen-activated protein kinase kinase kinase 3 fostamatinib MAP3K3 NA NA inhibitor small molecule approved,investigational NA NA Drugbank mitogen-activated protein kinase kinase kinase 4 fostamatinib MAP3K4 NA NA inhibitor small molecule approved,investigational NA NA Drugbank mitogen-activated protein kinase kinase kinase 6 fostamatinib MAP3K6 NA NA inhibitor small molecule approved,investigational NA NA Drugbank mitogen-activated protein kinase kinase kinase 9 fostamatinib MAP3K9 NA NA inhibitor small molecule approved,investigational NA NA Drugbank mitogen-activated protein kinase kinase kinase kinase 1 fostamatinib MAP4K1 NA NA inhibitor small molecule approved,investigational NA NA Drugbank mitogen-activated protein kinase kinase kinase kinase 2 fostamatinib MAP4K2 NA NA inhibitor small molecule approved,investigational NA NA Drugbank mitogen-activated protein kinase kinase kinase kinase 3 fostamatinib MAP4K3 NA NA inhibitor small molecule approved,investigational NA NA Drugbank mitogen-activated protein kinase kinase kinase kinase 4 fostamatinib MAP4K4 NA NA inhibitor small molecule approved,investigational NA NA Drugbank mitogen-activated protein kinase kinase kinase kinase 5 fostamatinib MAP4K5 NA NA inhibitor small molecule approved,investigational NA NA Drugbank mitogen-activated protein kinase kinase kinase mlt fostamatinib ZAK NA NA inhibitor small molecule approved,investigational NA NA Drugbank mu-type opioid receptor metenkefalin OPRM1 NA NA agonist small molecule investigational NA NA Drugbank muscle, skeletal receptor tyrosine-protein kinase fostamatinib MUSK NA NA inhibitor small molecule approved,investigational NA NA Drugbank myosin-iiia fostamatinib MYO3A NA NA inhibitor small molecule approved,investigational NA NA Drugbank myosin light chain kinase 2, skeletal/cardiac muscle fostamatinib MYLK2 NA NA inhibitor small molecule approved,investigational NA NA Drugbank myosin light chain kinase 3 fostamatinib MYLK3 NA NA inhibitor small molecule approved,investigational NA NA Drugbank myosin light chain kinase family member 4 fostamatinib MYLK4 NA NA inhibitor small molecule approved,investigational NA NA Drugbank myosin light chain kinase, smooth muscle fostamatinib MYLK NA NA inhibitor small molecule approved,investigational NA NA Drugbank nitric oxide synthase, inducible dexamethasone NOS2 NA NA negative modulator small molecule approved,investigational,vet_approved NA NA Drugbank nitric oxide synthase, inducible dexamethasone acetate NOS2 NA NA negative modulator small molecule approved,investigational,vet_approved NA NA Drugbank non-receptor tyrosine-protein kinase tnk1 fostamatinib TNK1 NA NA inhibitor small molecule approved,investigational NA NA Drugbank non-receptor tyrosine-protein kinase tyk2 baricitinib TYK2 NA NA inhibitor small molecule approved,investigational NA NA Drugbank non-receptor tyrosine-protein kinase tyk2 fostamatinib TYK2 NA NA inhibitor small molecule approved,investigational NA NA Drugbank non-receptor tyrosine-protein kinase tyk2 ruxolitinib TYK2 NA NA inhibitor small molecule approved NA NA Drugbank nt-3 growth factor receptor fostamatinib NTRK3 NA NA inhibitor small molecule approved,investigational NA NA Drugbank nuak family snf1-like kinase 1 fostamatinib NUAK1 NA NA inhibitor small molecule approved,investigational NA NA Drugbank nuak family snf1-like kinase 2 fostamatinib NUAK2 NA NA inhibitor small molecule approved,investigational NA NA Drugbank nuclear receptor subfamily 0 group b member 1 dexamethasone NR0B1 NA NA stimulator small molecule approved,investigational,vet_approved NA NA Drugbank nuclear receptor subfamily 0 group b member 1 dexamethasone acetate NR0B1 NA NA stimulator small molecule approved,investigational,vet_approved NA NA Drugbank nuclear receptor subfamily 1 group i member 2 dexamethasone NR1I2 NA NA agonist small molecule approved,investigational,vet_approved NA NA Drugbank nuclear receptor subfamily 1 group i member 2 dexamethasone acetate NR1I2 NA NA agonist small molecule approved,investigational,vet_approved NA NA Drugbank nuclear receptor subfamily 1 group i member 2 ritonavir NR1I2 NA NA activator small molecule approved,investigational NA NA Drugbank p-glycoprotein 1 azvudine ABCB1 NA NA activator,regulator small molecule investigational NA NA Drugbank peripheral plasma membrane protein cask fostamatinib CASK NA NA inhibitor small molecule approved,investigational NA NA Drugbank phosphatidylinositol 4-kinase beta fostamatinib PI4KB NA NA inhibitor small molecule approved,investigational NA NA Drugbank phosphatidylinositol 4-phosphate 3-kinase c2 domain-containing subunit beta fostamatinib PIK3C2B NA NA inhibitor small molecule approved,investigational NA NA Drugbank phosphatidylinositol 4-phosphate 3-kinase c2 domain-containing subunit gamma fostamatinib PIK3C2G NA NA inhibitor small molecule approved,investigational NA NA Drugbank phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform fostamatinib PIK3CD NA NA inhibitor small molecule approved,investigational NA NA Drugbank phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform fostamatinib PIK3CG NA NA inhibitor small molecule approved,investigational NA NA Drugbank phosphatidylinositol 5-phosphate 4-kinase type-2 beta fostamatinib PIP4K2B NA NA inhibitor small molecule approved,investigational NA NA Drugbank phosphatidylinositol 5-phosphate 4-kinase type-2 gamma fostamatinib PIP4K2C NA NA inhibitor small molecule approved,investigational NA NA Drugbank phosphodiesterase enzymes pentoxifylline N/A NA NA inhibitor small molecule approved,investigational NA NA Drugbank phosphorylase b kinase gamma catalytic chain, skeletal muscle/heart isoform fostamatinib PHKG1 NA NA inhibitor small molecule approved,investigational NA NA Drugbank platelet-derived growth factor receptor alpha fostamatinib PDGFRA NA NA inhibitor small molecule approved,investigational NA NA Drugbank platelet-derived growth factor receptor beta fostamatinib PDGFRB NA NA inhibitor small molecule approved,investigational NA NA Drugbank protein-arginine deiminase type-4 azithromycin PADI4 NA NA inhibitor small molecule approved NA NA Drugbank protein-tyrosine kinase 2-beta fostamatinib PTK2B NA NA inhibitor small molecule approved,investigational NA NA Drugbank protein-tyrosine kinase 6 fostamatinib PTK6 NA NA inhibitor small molecule approved,investigational NA NA Drugbank protein kinase c delta type fostamatinib PRKCD NA NA inhibitor small molecule approved,investigational NA NA Drugbank protein kinase c epsilon type fostamatinib PRKCE NA NA inhibitor small molecule approved,investigational NA NA Drugbank protein kinase c gamma type (prkcg) fostamatinib PRKCG NA NA inhibitor small molecule approved,investigational NA NA Drugbank protein kinase c iota type fostamatinib PRKCI NA NA inhibitor small molecule approved,investigational NA NA Drugbank protein kinase c theta type fostamatinib PRKCQ NA NA inhibitor small molecule approved,investigational NA NA Drugbank proto-oncogene tyrosine-protein kinase receptor ret fostamatinib RET NA NA inhibitor small molecule approved,investigational NA NA Drugbank proto-oncogene tyrosine-protein kinase ros fostamatinib ROS1 NA NA inhibitor small molecule approved,investigational NA NA Drugbank proto-oncogene tyrosine-protein kinase src fostamatinib SRC NA NA inhibitor small molecule approved,investigational NA NA Drugbank raf proto-oncogene serine/threonine-protein kinase fostamatinib RAF1 NA NA inhibitor small molecule approved,investigational NA NA Drugbank receptor-interacting serine/threonine-protein kinase 1 fostamatinib RIPK1 NA NA inhibitor small molecule approved,investigational NA NA Drugbank receptor-interacting serine/threonine-protein kinase 2 fostamatinib RIPK2 NA NA inhibitor small molecule approved,investigational NA NA Drugbank receptor-interacting serine/threonine-protein kinase 4 fostamatinib RIPK4 NA NA inhibitor small molecule approved,investigational NA NA Drugbank receptor-type tyrosine-protein kinase flt3 fostamatinib FLT3 NA NA inhibitor small molecule approved,investigational NA NA Drugbank receptor-type tyrosine-protein phosphatase beta razuprotafib PTPRB NA NA inhibitor small molecule investigational NA NA Drugbank receptor tyrosine-protein kinase erbb-2 fostamatinib ERBB2 NA NA inhibitor small molecule approved,investigational NA NA Drugbank receptor tyrosine-protein kinase erbb-4 fostamatinib ERBB4 NA NA inhibitor small molecule approved,investigational NA NA Drugbank rho-associated protein kinase 2 fostamatinib ROCK2 NA NA inhibitor small molecule approved,investigational NA NA Drugbank ribosomal protein s6 kinase alpha-1 fostamatinib RPS6KA1 NA NA inhibitor small molecule approved,investigational NA NA Drugbank ribosomal protein s6 kinase alpha-3 fostamatinib RPS6KA3 NA NA inhibitor small molecule approved,investigational NA NA Drugbank ribosomal protein s6 kinase alpha-6 fostamatinib RPS6KA6 NA NA inhibitor small molecule approved,investigational NA NA Drugbank serine/threonine-protein kinase 10 fostamatinib STK10 NA NA inhibitor small molecule approved,investigational NA NA Drugbank serine/threonine-protein kinase 16 fostamatinib STK16 NA NA inhibitor small molecule approved,investigational NA NA Drugbank serine/threonine-protein kinase 17a fostamatinib STK17A NA NA inhibitor small molecule approved,investigational NA NA Drugbank serine/threonine-protein kinase 17b fostamatinib STK17B NA NA inhibitor small molecule approved,investigational NA NA Drugbank serine/threonine-protein kinase 24 fostamatinib STK24 NA NA inhibitor small molecule approved,investigational NA NA Drugbank serine/threonine-protein kinase 3 fostamatinib STK3 NA NA inhibitor small molecule approved,investigational NA NA Drugbank serine/threonine-protein kinase 32a fostamatinib STK32A NA NA inhibitor small molecule approved,investigational NA NA Drugbank serine/threonine-protein kinase 33 fostamatinib STK33 NA NA inhibitor small molecule approved,investigational NA NA Drugbank serine/threonine-protein kinase 35 fostamatinib STK35 NA NA inhibitor small molecule approved,investigational NA NA Drugbank serine/threonine-protein kinase 36 fostamatinib STK36 NA NA inhibitor small molecule approved,investigational NA NA Drugbank serine/threonine-protein kinase 38 fostamatinib STK38 NA NA inhibitor small molecule approved,investigational NA NA Drugbank serine/threonine-protein kinase 38-like fostamatinib STK38L NA NA inhibitor small molecule approved,investigational NA NA Drugbank serine/threonine-protein kinase b-raf fostamatinib BRAF NA NA inhibitor small molecule approved,investigational NA NA Drugbank serine/threonine-protein kinase chk1 fostamatinib CHEK1 NA NA inhibitor small molecule approved,investigational NA NA Drugbank serine/threonine-protein kinase chk2 fostamatinib CHEK2 NA NA inhibitor small molecule approved,investigational NA NA Drugbank serine/threonine-protein kinase d1 fostamatinib PRKD1 NA NA inhibitor small molecule approved,investigational NA NA Drugbank serine/threonine-protein kinase dclk1 fostamatinib DCLK1 NA NA inhibitor small molecule approved,investigational NA NA Drugbank serine/threonine-protein kinase dclk2 fostamatinib DCLK2 NA NA inhibitor small molecule approved,investigational NA NA Drugbank serine/threonine-protein kinase dclk3 fostamatinib DCLK3 NA NA inhibitor small molecule approved,investigational NA NA Drugbank serine/threonine-protein kinase ick fostamatinib ICK NA NA inhibitor small molecule approved,investigational NA NA Drugbank serine/threonine-protein kinase lats1 fostamatinib LATS1 NA NA inhibitor small molecule approved,investigational NA NA Drugbank serine/threonine-protein kinase mark1 fostamatinib MARK1 NA NA inhibitor small molecule approved,investigational NA NA Drugbank serine/threonine-protein kinase mark2 fostamatinib MARK2 NA NA inhibitor small molecule approved,investigational NA NA Drugbank serine/threonine-protein kinase mrck gamma fostamatinib CDC42BPG NA NA inhibitor small molecule approved,investigational NA NA Drugbank serine/threonine-protein kinase mst4 fostamatinib STK26 NA NA inhibitor small molecule approved,investigational NA NA Drugbank serine/threonine-protein kinase mtor fostamatinib MTOR NA NA inhibitor small molecule approved,investigational NA NA Drugbank serine/threonine-protein kinase n1 fostamatinib PKN1 NA NA inhibitor small molecule approved,investigational NA NA Drugbank serine/threonine-protein kinase n2 fostamatinib PKN2 NA NA inhibitor small molecule approved,investigational NA NA Drugbank serine/threonine-protein kinase nek1 fostamatinib NEK1 NA NA inhibitor small molecule approved,investigational NA NA Drugbank serine/threonine-protein kinase nek11 fostamatinib NEK11 NA NA inhibitor small molecule approved,investigational NA NA Drugbank serine/threonine-protein kinase nek2 fostamatinib NEK2 NA NA inhibitor small molecule approved,investigational NA NA Drugbank serine/threonine-protein kinase nek3 fostamatinib NEK3 NA NA inhibitor small molecule approved,investigational NA NA Drugbank serine/threonine-protein kinase nek4 fostamatinib NEK4 NA NA inhibitor small molecule approved,investigational NA NA Drugbank serine/threonine-protein kinase nek5 fostamatinib NEK5 NA NA inhibitor small molecule approved,investigational NA NA Drugbank serine/threonine-protein kinase nek9 fostamatinib NEK9 NA NA inhibitor small molecule approved,investigational NA NA Drugbank serine/threonine-protein kinase nim1 fostamatinib NIM1K NA NA inhibitor small molecule approved,investigational NA NA Drugbank serine/threonine-protein kinase osr1 fostamatinib OXSR1 NA NA inhibitor small molecule approved,investigational NA NA Drugbank serine/threonine-protein kinase pak 1 fostamatinib PAK1 NA NA inhibitor small molecule approved,investigational NA NA Drugbank serine/threonine-protein kinase pak 2 fostamatinib PAK2 NA NA inhibitor small molecule approved,investigational NA NA Drugbank serine/threonine-protein kinase pak 3 fostamatinib PAK3 NA NA inhibitor small molecule approved,investigational NA NA Drugbank serine/threonine-protein kinase pak 4 fostamatinib PAK4 NA NA inhibitor small molecule approved,investigational NA NA Drugbank serine/threonine-protein kinase pak 5 fostamatinib PAK5 NA NA inhibitor small molecule approved,investigational NA NA Drugbank serine/threonine-protein kinase pak 6 fostamatinib PAK6 NA NA inhibitor small molecule approved,investigational NA NA Drugbank serine/threonine-protein kinase pim-1 fostamatinib PIM1 NA NA inhibitor small molecule approved,investigational NA NA Drugbank serine/threonine-protein kinase pim-3 fostamatinib PIM3 NA NA inhibitor small molecule approved,investigational NA NA Drugbank serine/threonine-protein kinase plk1 fostamatinib PLK1 NA NA inhibitor small molecule approved,investigational NA NA Drugbank serine/threonine-protein kinase plk2 fostamatinib PLK2 NA NA inhibitor small molecule approved,investigational NA NA Drugbank serine/threonine-protein kinase plk3 fostamatinib PLK3 NA NA inhibitor small molecule approved,investigational NA NA Drugbank serine/threonine-protein kinase plk4 fostamatinib PLK4 NA NA inhibitor small molecule approved,investigational NA NA Drugbank serine/threonine-protein kinase prp4 homolog fostamatinib PRPF4B NA NA inhibitor small molecule approved,investigational NA NA Drugbank serine/threonine-protein kinase rio1 fostamatinib RIOK1 NA NA inhibitor small molecule approved,investigational NA NA Drugbank serine/threonine-protein kinase rio2 fostamatinib RIOK2 NA NA inhibitor small molecule approved,investigational NA NA Drugbank serine/threonine-protein kinase rio3 fostamatinib RIOK3 NA NA inhibitor small molecule approved,investigational NA NA Drugbank serine/threonine-protein kinase sbk1 fostamatinib SBK1 NA NA inhibitor small molecule approved,investigational NA NA Drugbank serine/threonine-protein kinase sgk3 fostamatinib SGK3 NA NA inhibitor small molecule approved,investigational NA NA Drugbank serine/threonine-protein kinase sik1 fostamatinib SIK1 NA NA inhibitor small molecule approved,investigational NA NA Drugbank serine/threonine-protein kinase sik2 fostamatinib SIK2 NA NA inhibitor small molecule approved,investigational NA NA Drugbank serine/threonine-protein kinase sik3 fostamatinib SIK3 NA NA inhibitor small molecule approved,investigational NA NA Drugbank serine/threonine-protein kinase tao1 fostamatinib TAOK1 NA NA inhibitor small molecule approved,investigational NA NA Drugbank serine/threonine-protein kinase tao2 fostamatinib TAOK2 NA NA inhibitor small molecule approved,investigational NA NA Drugbank serine/threonine-protein kinase tao3 fostamatinib TAOK3 NA NA inhibitor small molecule approved,investigational NA NA Drugbank serine/threonine-protein kinase tbk1 fostamatinib TBK1 NA NA inhibitor small molecule approved,investigational NA NA Drugbank serine/threonine-protein kinase tnni3k fostamatinib TNNI3K NA NA inhibitor small molecule approved,investigational NA NA Drugbank serine/threonine-protein kinase tousled-like 1 fostamatinib TLK1 NA NA inhibitor small molecule approved,investigational NA NA Drugbank serine/threonine-protein kinase tousled-like 2 fostamatinib TLK2 NA NA inhibitor small molecule approved,investigational NA NA Drugbank serine/threonine-protein kinase ulk1 fostamatinib ULK1 NA NA inhibitor small molecule approved,investigational NA NA Drugbank serine/threonine-protein kinase ulk2 fostamatinib ULK2 NA NA inhibitor small molecule approved,investigational NA NA Drugbank serine/threonine-protein kinase ulk3 fostamatinib ULK3 NA NA inhibitor small molecule approved,investigational NA NA Drugbank serine/threonine-protein kinase/endoribonuclease ire1 fostamatinib ERN1 NA NA inhibitor small molecule approved,investigational NA NA Drugbank snf-related serine/threonine-protein kinase fostamatinib SNRK NA NA inhibitor small molecule approved,investigational NA NA Drugbank sphingosine 1-phosphate receptor 1 fingolimod S1PR1 NA NA modulator small molecule approved,investigational NA NA Drugbank sphingosine 1-phosphate receptor 3 fingolimod S1PR3 NA NA modulator small molecule approved,investigational NA NA Drugbank sphingosine 1-phosphate receptor 4 fingolimod S1PR4 NA NA modulator small molecule approved,investigational NA NA Drugbank sphingosine 1-phosphate receptor 5 fingolimod S1PR5 NA NA modulator small molecule approved,investigational NA NA Drugbank sphingosine kinase 2 opaganib SPHK2 NA NA inhibitor small molecule investigational NA NA Drugbank ste20-like serine/threonine-protein kinase fostamatinib SLK NA NA inhibitor small molecule approved,investigational NA NA Drugbank ste20/sps1-related proline-alanine-rich protein kinase fostamatinib STK39 NA NA inhibitor small molecule approved,investigational NA NA Drugbank suppressor of tumorigenicity 14 protein camostat ST14 NA NA inhibitor small molecule experimental NA NA Drugbank testis-specific serine/threonine-protein kinase 1 fostamatinib TSSK1B NA NA inhibitor small molecule approved,investigational NA NA Drugbank tgf-beta receptor type-1 fostamatinib TGFBR1 NA NA inhibitor small molecule approved,investigational NA NA Drugbank tgf-beta receptor type-2 fostamatinib TGFBR2 NA NA inhibitor small molecule approved,investigational NA NA Drugbank toll-like receptor 7 hydroxychloroquine TLR7 NA NA antagonist small molecule approved NA NA Drugbank toll-like receptor 9 chloroquine TLR9 NA NA inhibitor small molecule approved,investigational,vet_approved NA NA Drugbank toll-like receptor 9 hydroxychloroquine TLR9 NA NA antagonist small molecule approved NA NA Drugbank traf2 and nck-interacting protein kinase fostamatinib TNIK NA NA inhibitor small molecule approved,investigational NA NA Drugbank transmembrane protease serine 2 bromhexine TMPRSS2 NA NA N/A small molecule approved NA NA Drugbank transmembrane protease serine 2 camostat TMPRSS2 NA NA inhibitor small molecule experimental NA NA Drugbank trypsin-1 camostat PRSS1 NA NA inhibitor small molecule experimental NA NA Drugbank tumor necrosis factor chloroquine TNF NA NA inhibitor small molecule approved,investigational,vet_approved NA NA Drugbank tyrosine-protein kinase abl1 fostamatinib ABL1 NA NA inhibitor small molecule approved,investigational NA NA Drugbank tyrosine-protein kinase abl2 fostamatinib ABL2 NA NA inhibitor small molecule approved,investigational NA NA Drugbank tyrosine-protein kinase blk fostamatinib BLK NA NA inhibitor small molecule approved,investigational NA NA Drugbank tyrosine-protein kinase btk abivertinib BTK NA NA inhibitor small molecule investigational NA NA Drugbank tyrosine-protein kinase btk fostamatinib BTK NA NA inhibitor small molecule approved,investigational NA NA Drugbank tyrosine-protein kinase csk fostamatinib CSK NA NA inhibitor small molecule approved,investigational NA NA Drugbank tyrosine-protein kinase fer fostamatinib FER NA NA inhibitor small molecule approved,investigational NA NA Drugbank tyrosine-protein kinase fes/fps fostamatinib FES NA NA inhibitor small molecule approved,investigational NA NA Drugbank tyrosine-protein kinase fgr fostamatinib FGR NA NA inhibitor small molecule approved,investigational NA NA Drugbank tyrosine-protein kinase frk fostamatinib FRK NA NA inhibitor small molecule approved,investigational NA NA Drugbank tyrosine-protein kinase fyn fostamatinib FYN NA NA inhibitor small molecule approved,investigational NA NA Drugbank tyrosine-protein kinase hck fostamatinib HCK NA NA inhibitor small molecule approved,investigational NA NA Drugbank tyrosine-protein kinase itk/tsk fostamatinib ITK NA NA inhibitor small molecule approved,investigational NA NA Drugbank tyrosine-protein kinase jak1 baricitinib JAK1 NA NA inhibitor small molecule approved,investigational NA NA Drugbank tyrosine-protein kinase jak1 fostamatinib JAK1 NA NA inhibitor small molecule approved,investigational NA NA Drugbank tyrosine-protein kinase jak1 ruxolitinib JAK1 NA NA inhibitor small molecule approved NA NA Drugbank tyrosine-protein kinase jak2 baricitinib JAK2 NA NA inhibitor small molecule approved,investigational NA NA Drugbank tyrosine-protein kinase jak2 fostamatinib JAK2 NA NA inhibitor small molecule approved,investigational NA NA Drugbank tyrosine-protein kinase jak2 ruxolitinib JAK2 NA NA inhibitor small molecule approved NA NA Drugbank tyrosine-protein kinase jak3 baricitinib JAK3 NA NA inhibitor small molecule approved,investigational NA NA Drugbank tyrosine-protein kinase jak3 fostamatinib JAK3 NA NA inhibitor small molecule approved,investigational NA NA Drugbank tyrosine-protein kinase jak3 ruxolitinib JAK3 NA NA inhibitor small molecule approved NA NA Drugbank tyrosine-protein kinase lck fostamatinib LCK NA NA inhibitor small molecule approved,investigational NA NA Drugbank tyrosine-protein kinase lyn fostamatinib LYN NA NA inhibitor small molecule approved,investigational NA NA Drugbank tyrosine-protein kinase mer fostamatinib MERTK NA NA inhibitor small molecule approved,investigational NA NA Drugbank tyrosine-protein kinase receptor tie-1 fostamatinib TIE1 NA NA inhibitor small molecule approved,investigational NA NA Drugbank tyrosine-protein kinase receptor tyro3 fostamatinib TYRO3 NA NA inhibitor small molecule approved,investigational NA NA Drugbank tyrosine-protein kinase receptor ufo fostamatinib AXL NA NA inhibitor small molecule approved,investigational NA NA Drugbank tyrosine-protein kinase srms fostamatinib SRMS NA NA inhibitor small molecule approved,investigational NA NA Drugbank tyrosine-protein kinase syk fostamatinib SYK NA NA inhibitor small molecule approved,investigational NA NA Drugbank tyrosine-protein kinase tec fostamatinib TEC NA NA inhibitor small molecule approved,investigational NA NA Drugbank tyrosine-protein kinase txk fostamatinib TXK NA NA inhibitor small molecule approved,investigational NA NA Drugbank tyrosine-protein kinase yes fostamatinib YES1 NA NA inhibitor small molecule approved,investigational NA NA Drugbank tyrosine-protein kinase zap-70 fostamatinib ZAP70 NA NA inhibitor small molecule approved,investigational NA NA Drugbank udp-glucuronosyltransferase 1-1 fostamatinib UGT1A1 NA NA inhibitor small molecule approved,investigational NA NA Drugbank uncharacterized serine/threonine-protein kinase sbk3 fostamatinib SBK3 NA NA inhibitor small molecule approved,investigational NA NA Drugbank vascular endothelial growth factor a bevacizumab VEGFA NA NA N/A biotech approved,investigational NA NA Drugbank vascular endothelial growth factor receptor 1 fostamatinib FLT1 NA NA inhibitor small molecule approved,investigational NA NA Drugbank vascular endothelial growth factor receptor 2 fostamatinib KDR NA NA inhibitor small molecule approved,investigational NA NA Drugbank vascular endothelial growth factor receptor 3 fostamatinib FLT4 NA NA inhibitor small molecule approved,investigational NA NA Drugbank vesicular monoamine transporter 2 (vmat2) fostamatinib VMAT2 NA NA inhibitor small molecule approved,investigational NA NA Drugbank wee1-like protein kinase fostamatinib WEE1 NA NA inhibitor small molecule approved,investigational NA NA Drugbank